Notice of Results

RNS Number : 7719Z

Avacta Group PLC

05 September 2018

 

                                                                                                                                                          5 September 2018                            

Avacta Group plc

("Avacta", the "Group" or the "Company")

Notice of Results

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, will announce its financial results for the year ended 31 July 2018 on Tuesday, 2 October 2018.

An analyst briefing given by Alastair Smith, Chief Executive Officer and Tony Gardiner, Chief Financial Officer, will be held at 09.30 hrs on Tuesday, 2 October 2018 at finnCap's offices, 60 New Broad St, London EC2M 1JJ.

- Ends -

For further information from Avacta Group plc, please contact:

Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer	Tel:  [phone] www.avacta.com
finnCap Ltd Geoff Nash / Giles Rolls - Nominated Adviser Tim Redfern / Nikita Jain - Corporate Broking WG Partners Nigel Birks / Nigel Barnes David Wilson / Claes Spang	Tel:  [phone] www.finncap.com Tel:  [phone] Tel:  [phone] www.wgpartners.co.uk
Zyme Communications (Trade and Regional Media) Katie Odgaard Yellow Jersey (Financial Media and IR) Sarah Hollins	Tel: [phone] [e-mail]  Tel: [phone] [e-mail]

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer^® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability.  Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

 

END

 

 

NORSSEESLFASESU